Tag:

Novartis

Latest Headlines

Latest Headlines

Novartis' psoriasis drug looks good enough to approve, FDA staff says

The benefits of Novartis' new anti-inflammatory treatment outweigh its risks, according to FDA reviewers, an opinion that improves the odds of approval for a drug the company hopes can bring in blockbuster sales.

Bexsero could be cost-effective for England, model says--but not at Novartis' price

What's the value of Novartis' meningitis B vaccine, Bexsero, to the U.K.? It's a question the company and the country's government have been debating for months now, unable to come to terms on a reasonable price for the jab. But medical journal The BMJ might have an answer.

Penn-Novartis team 'amazed' at remissions, responses in leukemia CAR-T study

Investigators working on Novartis' personalized CTL019 CAR-T program at the University of Pennsylvania say that 90% of a small group of children suffering from very advanced cases of treatment-resistant acute lymphoblastic leukemia achieved complete remission after being treated in the newly updated trial.

Novartis breaks out in song with MS campaign featuring David Osmond

Novartis has added a bit of pop to its already extensive Gilenya marketing. Not content with a Twitter feed, a YouTube channel, a self-management smartphone app, and a gaggle of awareness pushes, the Swiss drugmaker is now in the music business.

Drug delivery: Fertile ground for pharma-device company partnerships?

BOSTON-- Whether through collaboration with academia or buyouts of smaller players, panelists at the Partnership Opportunities in Drug Delivery conference concurred that Big Pharma is increasingly looking externally for innovation and using its size and financial to power candidates through clinicial and onto the market.

Novartis' Russian growth plans get delayed

Novartis is reportedly caught between EU sanctions on Russia and the dictates of Russian President Vladimir Putin, who has told Western drugmakers that he expects them to build plants and transfer technology as the price of admission to the growing market.

UPDATED: Novartis faces technical issues on $150M plant in Russia

Construction of a $150 million plant that Novartis is building near St. Petersburg in Russia has been halted because of "technical reasons," just short of completion.

Novartis joins an Atlas syndicate to back cancer drug upstart Raze

Atlas Venture is launching one of its newly built biotechs with a Series A of $24 million, a founding partner on the board, a pair of its entrepreneurs heading the crew and some marquee investors in the syndicate, which includes Novartis. They've begun a voyage of discovery with Raze Therapeutics, part of Atlas's growing fleet of startups, to see how far they can go down a pathway that offers its investigators a shot at throwing a monkey wrench into the metabolic processes cancer uses to thrive.

India's NPPA fines Novartis $49M as price cap battles rage on

India's National Pharmaceutical Pricing Authority has fined Novartis the equivalent of $49 million for overpricing its popular pain drug Voveran, and Novartis has responded by challenging NPPA's authority to do so. The fine is just the latest move in an escalating battle between drugmakers and the NPPA.

Covance and Novartis team up with eyes on Big Data

Covance has joined forces with Novartis to develop new ways to help drug developers quickly integrate and analyze huge swaths of study data.